A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics.
作者信息
Lakhanpal Amit, Brahn Ernest
机构信息
Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA.
Division of Rheumatology, UCLA School of Medicine, Los Angeles, CA, USA.
出版信息
Eur J Rheumatol. 2020 Aug;7(Suppl 2):S102-S106. doi: 10.5152/eurjrheum.2020.2065. Epub 2020 May 22.
Abstract
摘要
相似文献
1
A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics.关于新型冠状病毒肺炎（严重急性呼吸综合征冠状病毒2）治疗方法现代进展的观点。
Eur J Rheumatol. 2020 Aug;7(Suppl 2):S102-S106. doi: 10.5152/eurjrheum.2020.2065. Epub 2020 May 22.
2
Distinct Molecular Mechanisms Characterizing Pathogenesis of SARS-CoV-2.明确表征 SARS-CoV-2 发病机制的分子机制。
J Microbiol Biotechnol. 2022 Sep 28;32(9):1073-1085. doi: 10.4014/jmb.2206.06064. Epub 2022 Aug 23.
3
SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）/COVID-19 及其相关疗法和疫苗的研究进展，以应对这一新兴的大流行病。
Ann Clin Microbiol Antimicrob. 2020 Sep 2;19(1):40. doi: 10.1186/s12941-020-00384-w.
4
Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.重新利用治疗方法以潜在治疗 SARS-CoV-2：综述。
Viruses. 2020 Jun 30;12(7):705. doi: 10.3390/v12070705.
5
Structural insights into SARS-CoV-2 infection and therapeutics development.SARS-CoV-2 感染与治疗药物研发的结构生物学研究进展
Stem Cell Res. 2021 Apr;52:102219. doi: 10.1016/j.scr.2021.102219. Epub 2021 Feb 2.
6
Coronavirus Disease Pandemic (COVID-19): Challenges and a Global Perspective.冠状病毒病大流行（COVID-19）：挑战与全球视角
Pathogens. 2020 Jun 28;9(7):519. doi: 10.3390/pathogens9070519.
7
Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans.严重急性呼吸综合征冠状病毒 2：人类疾病的表现及治疗和预防方法。
Comp Med. 2021 Oct 1;71(5):342-358. doi: 10.30802/AALAS-CM-21-000011. Epub 2021 Sep 17.
8
Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments.基于纳米材料的平台在抗击 COVID-19 方面的进展：诊断、预防、治疗和疫苗开发。
ACS Appl Bio Mater. 2022 Jun 20;5(6):2431-2460. doi: 10.1021/acsabm.2c00123. Epub 2022 May 18.
9
Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus.新型冠状病毒肺炎的治疗现状：对该新型病毒治疗方法的分子机制和疗效的了解。
Int J Mol Sci. 2022 Jul 12;23(14):7702. doi: 10.3390/ijms23147702.
10
Aptamers targeting SARS-COV-2: a promising tool to fight against COVID-19.针对 SARS-COV-2 的适配体：抗击 COVID-19 的有前途工具。
Trends Biotechnol. 2023 Apr;41(4):528-544. doi: 10.1016/j.tibtech.2022.07.012. Epub 2022 Aug 1.
本文引用的文献
1
Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.羟氯喹在美国 COVID-19 住院患者中的使用效果。
Med. 2020 Dec 18;1(1):114-127.e3. doi: 10.1016/j.medj.2020.06.001. Epub 2020 Jun 5.
2
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
3
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.新型冠状病毒感染恢复期个体中 SARS-CoV-2 特异性体液和细胞免疫的检测。
Immunity. 2020 Jun 16;52(6):971-977.e3. doi: 10.1016/j.immuni.2020.04.023. Epub 2020 May 3.
4
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.干扰素 beta-1b、洛匹那韦利托那韦和利巴韦林三联治疗住院 COVID-19 患者：一项开放标签、随机、2 期试验。
Lancet. 2020 May 30;395(10238):1695-1704. doi: 10.1016/S0140-6736(20)31042-4. Epub 2020 May 10.
5
Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series.在中重度新型冠状病毒肺炎中使用阿那白滞素靶向炎症级联反应：病例系列
Ann Rheum Dis. 2020 Oct;79(10):1381-1382. doi: 10.1136/annrheumdis-2020-217706. Epub 2020 May 6.
6
What policy makers need to know about COVID-19 protective immunity.政策制定者需要了解的关于新冠病毒保护性免疫的信息。
Lancet. 2020 May 16;395(10236):1527-1529. doi: 10.1016/S0140-6736(20)30985-5. Epub 2020 Apr 27.
7
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.美国风湿病学会在 COVID-19 大流行期间成人患者风湿性疾病管理指南：第 1 版。
Arthritis Rheumatol. 2020 Aug;72(8):1241-1251. doi: 10.1002/art.41301. Epub 2020 Jun 5.
8
Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2.揭示羟氯喹在新型冠状病毒肺炎中的证据
Crit Care. 2020 Apr 28;24(1):182. doi: 10.1186/s13054-020-02894-7.
9
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.美国传染病学会关于2019冠状病毒病患者治疗与管理的指南
Clin Infect Dis. 2020 Apr 27. doi: 10.1093/cid/ciaa478.
10
Targeting potential drivers of COVID-19: Neutrophil extracellular traps.靶向 COVID-19 的潜在驱动因素：中性粒细胞胞外陷阱。
J Exp Med. 2020 Jun 1;217(6). doi: 10.1084/jem.20200652.
Zotero 插件